Quality of life in low vision patients is deeply conditioned by their visual ability, and increased rates of depression, domestic injury, and need for caregiver assistance can be expected as a result of low performance. Much effort have been made recently in order to develop new tools and aids for rehabilitation of low vision, and this research has led to better knowledge of visual function and increased the likelihood of new therapies in the future. Modern low vision rehabilitation is the result of recent advances in science and technology, and will soon have an important role in people with vision impairment, numbers of whom are likely to increase, give the increasing age of the population. This review outlines scientific developments in low vision rehabilitation based on a search of the literature, covers the role of digital technology and advances in neurofunctional rehabilitation, and the possibility of restoring vision by use of retinal prostheses and cellular therapy.

This article shows the first application of the new microperimeter MP3 in patients with RP, which has proven to be very sensitive in detecting functional abnormalities in all the patients. Future studies should investigate the relationships among photoreceptor cell loss, retinal sensitivity, and fixation in patients with RP.

No abstract

Coagulation and fibrinolysis studies were performed in 40 patients during the second week after occurrence of Retinal Vein Occlusion (RVO), in 35 patients with Diabetic Retinopathy of various degree and no thrombosis (DR), and in an age-sex matched control group.Euglobulin Lysis Time was markedly prolonged in 30% of RVO and in 44% of DR patients. Poor responders to venous stasis ranked around 35% in both groups. Urokinase inhibition was increased in one third of RVO and in about two thirds of DR patients. These and other findings like increase of Factor VIII or platelet aggregation were only seldom associated in the same subjects.Decreased plasma or tissue fibrinolysis is a frequent finding both in RVO and in DR and trials with drugs inducing a sustained increase of fibrinolytic activity are therefore justified in these conditions.